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Abstract
Background: Omphalocele is a congenital midline ventral body wall defect that can exist as isolated malformation
or as part of a syndrome. It can be considered one of the major and most frequent clinical manifestation of
Beckwith-Wiedemann Syndrome (BWS) in case of loss of methylation at KCNQ1OT1: Transcription Star Site-Differentially
Methylated Region (TSS-DMR) or in presence of CDKN1C mutations. The isolated form of the omphalocele accounts
approximately for about the 14% of the total cases and its molecular etiology has never been fully elucidated.
Methods: Given the tight relationship with BWS, we hypothesized that the isolated form of the omphalocele could
belong to the heterogeneous spectrum of the BWS associated features, representing an endophenotype with a clear
genetic connection. We therefore investigated genetic and epigenetic changes affecting BWS imprinted locus at
11p15.5 imprinted region, focusing in particular on the KCNQ1OT1:TSS DMR.
Results: We studied 21 cases of isolated omphalocele detected during pregnancy or at birth and identified the following
rare maternally inherited variants: i) the non-coding variant G > A at nucleotide 687 (NR_002728.3) at KCNQ1OT1:TSS-DMR,
which alters the methylation pattern of the imprinted allele, in one patient; ii) the deletion c.624-629delGGCCCC at exon 1
of CDKN1C, with unknown clinical significance, in two unrelated cases.
Conclusions: Taken together, these findings suggest that KCNQ1OT1:TSS-DMR could be a susceptibility locus for the
isolated omphalocele.
Keywords: Abdominal wall defects, Beckwith-Wiedemann syndrome, CDKN1C, Genomic imprinting, KCNQ1OT1:TSS-DMR,
Omphalocele
Background
Omphalocele is a congenital midline ventral body wall
defect characterized by the extrusion of abdominal
viscera through the base of the umbilical cord. This
malformation is related to the failure of the midgut loop
to return to the peritoneal cavity after its herniation into
the umbilical cord [1]. The incidence of omphalocele
diagnosed during pregnancy is approximately 1/5000;
however, this falls to 0.8/10,000 live births because of
pregnancy termination [2].
The definition of abdominal wall defects can be diffi-
cult, since a ruptured omphalocele may be misdiagnosed
as gastroschisis and an umbilical cord hernia can be
confused with a small omphalocele. Gastroschisis is
caused by vascular defects, does not involve the insertion
site of the umbilical cord, and is generally localized to the
right of the umbilicus [3]. Conversely, omphalocele results
from an enlargement of the umbilical ring due to the
migration failure of cephalic and/or lateral folds and
abdominal bands during early embryogenesis [4, 5].
Omphalocele may be syndromic or isolated. Of
syndromic cases, 54–57% are caused by aneuploidy, with
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a prevalence of trisomy 18 [6]. The remaining cases are
associated with a number of genetic conditions includ-
ing Beckwith-Wiedemann syndrome (BWS; MIM
130650), pentalogy of Cantrell (OMIM 313850), and
OEIS (Omphalocele, Exstrophy, Imperforate anus,
Spinal defects; OMIM 258040) [7–9]. Of these, BWS is
the most common syndrome associated with omphalo-
cele [10]. Indeed, isolated omphalocele can be the first
manifestation of a mild clinical form of BWS, in a simi-
lar way to isolated hemihyperplasia, which can be
predictive of BWS [11, 12]. BWS is genetically hetero-
geneous and may be caused by genomic, epigenetic, or
genetic alterations at the 11p15.5 chromosomal locus.
This region harbors two imprinted domains, IGF2/H19
and KCNQ1/CDKN1C, regulated by H19/IGF2:IG-
DMR (InterGenic - Differentially Methylated Region)
and KCNQ1OT1:TSS-DMR (Transcription Start Site –
Differentially Methylated Region), respectively. In
healthy individuals, H19/IGF2:IG-DMR is methylated
on the paternally derived allele and unmethylated on
the maternally inherited allele, resulting in the prefer-
ential expression of the paternal IGF2 and the maternal
H19. At KCNQ1OT1:TSS-DMR, the opposite methyla-
tion pattern is observed [11, 12]. The KCNQ1OT1:TSS-
DMR regulates the expression of CDKN1C and
KCNQ1, as well as other genes, including PHLDA and
SLC22A18. KCNQ1OT1:TSS-DMR is located within
intron 10 of KCNQ1 and encompasses the promoter of
the non-coding RNA KCNQ1OT1, which is orientated
in the antisense direction relative to KCNQ1. Fig. 1a
shows a schematic representation of the imprinted
locus. Physiological expression of KCNQ1OT1 from the
unmethylated paternal allele results in the bi-directional
silencing of its flanking imprinted genes [13]. Among
them, CDKN1C encodes P57 (alias KIP2), a tight-binding
inhibitor of several G1 cyclin/Cdk complexes, acting as a
negative regulator of cell proliferation [14]. The CDKN1C
gene contains three exons and 2 GC-rich introns; how-
ever, only exons 1 and 2 encode the functional P57
protein. P57 is composed of 316 amino acids and
consists of three structurally distinct domains: (i) the
N-terminal domain (aa 1–110), which has significant
similarity to the CdK-inhibitors, p21Cip1 and p27Kip1,
and is necessary for CdK inhibition; (ii) the central
highly polymorphic hexanucleotide repeat domain,
encoding a series of proline-alanine repeats (PAPA-re-
peats, aa 156–213) involved in Mitogen-Activated Protein
Kinase (MAPK) phosphorylation [15]; and (iii) the highly
conserved C-terminal region (QT domain) that exhibits
homology with p27Kip1 [16].
Fig. 1 Epigenetic and genetic regulation of the 11p15.5 imprinted locus. As shown in (a), the 11p15.5 imprinted locus presents with 2 domains
(Domain 1 and Domain 2) differentially regulated by H19/IGF2-IG and KCNQ1OT1:TSS DMRs, respectively. Transcribed genes are depicted in green,
silenced genes in red. On the maternal allele, the effect of the enhancer promotes the expression of H19, the most proximal gene, but not of
IGF2. This is the consequence of the CTCF binding to H19/IGF2-IG DMR located between the two genes. On the paternal allele, methylation of
this DMR prevents the binding of CTCF, allowing the expression of IGF2 and the silencing of H19. At KCNQ1OT1:TSS DMR the opposite methylation
pattern is observed. This DMR is methylated on the maternal allele and not on the paternal one. Thus, maternal repression of KCNQ10T allows the
expression of CDKN1C and KCNQ1, while the expression of the KCNQ10T on the paternal allele inhibits the transcription of the flanking genes CDKN1C
and KCNQ1. CDKN1C gene and protein structure are depicted in (b). White striped boxes identify the 5′- and 3′-UTRs and the black portion represents
the coding sequence of the gene. CDKN1C encodes for P57 protein (alias KIP2), composed of the three functional domains depicted with different
colors. Black arrows indicate previously identified truncating mutations inside the PAPA domain; red arrow points out the susceptibility variant
p.A209_P210del identified in this paper
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Decreased CDKN1C activity due to genetic variants,
loss of KCNQ1OT1:TSS-DMR maternal methylation,
or changes in gene copy number is associated with
BWS. Forty to 50 % of BWS cases present with loss
of KCNQ1OT1:TSS-DMR maternal methylation [17].
Abdominal wall defects are very common in cases
with hypomethylation: 42.1% of patients have om-
phalocele, 20% present with umbilical hernia, and
approximately 12% with diastasis recti [18].
Concerning genetic variants, causative CDKN1C point
mutations are maternally inherited and cause protein
loss-of-function. Point mutations of CDKN1C are
present in up to 5% of sporadic and 50% of familial cases
of BWS [19]. Most frequently, CDKN1C mutations are
truncating or frameshift and are distributed along the
entire coding region; conversely, missense mutations are
mainly localized in the CDK-like domain [14]. Almost
90% of BWS patients with CDKN1C mutations have
abdominal wall defects [18]; in particular, omphalocele
occurs in 71.6% of these cases [18]. Finally, structural
chromosome alterations such as deletions/duplications
(1–2% of BWS cases) and uniparental disomy (UPD) at
11p15.5 involving CDKN1C (10–20% of BWS cases) [15]
cause umbilical hernias in about half of patients,
whereas in others no abdominal wall defects are
described [18]. Thus, omphalocele can be considered
one of the major and most frequent clinical manifesta-
tions of BWS in cases of KCNQ1OT1:TSS-DMR loss of
methylation or CDKN1C mutations [20, 21].
A well-defined (epi)genotype–phenotype correlation
exists for omphalocele in BWS: it is caused by
KCNQ1OT1:TSS-DMR loss of methylation in 86% of the
cases, by CDKN1C mutation in 7%, and by UPD or
H19/IGF2:IG-DMR gain of methylation in <10% of
patients [18].
Approximatively 14% of all cases of omphalocele can
be classified as isolated [2]. Despite several studies inves-
tigating the genetic causes [22–25] or environmental risk
factors [24] involved in this malformation, the etiology
of isolated omphalocele has not been fully elucidated.
Kanagawa et al. [23] described an extensive family with
vertical transmission of isolated omphalocele, with nine
subjects over three generations affected, suggesting an
autosomal dominant pattern of inheritance. This finding
was in agreement with five other previously reported
pedigrees demonstrating vertical transmission of isolated
omphalocele [25]. The same authors also described five
families with an inheritance consistent with an auto-
somal recessive pattern [25]. Despite these observations,
inherited alterations have never been identified in these
families. More recently, a genomic duplication was
found in a large pedigree with autosomal dominant
transmission of isolated omphalocele [22]. Genetic
analysis revealed that all affected individuals were
positive for a duplication at chromosome 1p31.3,
suggesting the involvement of one or more genes in the
duplicated region, including FOXD3, ALG6, ITGB3BP,
KIAA1799, DLEU2L, PGM1, and the proximal portion
of ROR1 [22].
Methods
The early genetic characterization of newborns with
omphalocele initially defined as isolated, together with a
careful follow-up, can help pre- and/or post-natal
clinical management and possibly enable definition of
recurrence risk.
We studied 21 cases with isolated omphalocele diag-
nosed during pregnancy or at birth and we investigated
molecular changes associated with BWS to determine
whether isolated omphalocele could belong to the het-
erogeneous spectrum of BWS associated features. We
did not consider other conditions (Pentalogy of Cantrell
and OEIS) since the affected individuals usually present
with complex and more severe phenotypes. Finally, we
investigated whether genomic alterations at 1p31 or at
other chromosome regions could be associated with this
clinical manifestation.
Participants
The study included 21 patients (10 females and 11
males) with isolated omphalocele confirmed at birth,
examined from 2013 to 2015 at the Department of
Pediatric Surgery of Fondazione IRCCS Ca′ Granda
Ospedale Maggiore Policlinico, Milan (Italy). Patients
came to the attention of the pediatric clinicians of our
hospital for diagnostic purposes in the period specified
above. They (or their parents, in case of patients were
underage) gave their consent to the possible future use
of their genetic material for research purposes.
The clinical features of the population are described in
Table 1. In details, seven cases were diagnosed at birth
and 14 during prenatal ultrasound screening (US).
Gestational age at diagnosis, in these latter cases, ranged
from 12 to 26 Weeks of gestation (Wog).
The omphaloceles were classified as minor (diameter
< 5 cm), medium (diameter = 5 cm) or “giant” (diam-
eter > 5 \cm), according to literature [26]. Of the 15
cases with minor omphalocele, seven were diagnosed at
birth. Only two fetuses (C11 and C20) were detected
with both omphalocele and umbilical cord abnormal-
ities (funicular cyst and multiple cysts) (Table 1).
Conception was spontaneous in 19 cases. Two cases,
C2 and C6, were conceived by ICSI (intracytoplasmic
sperm injection), with egg donation in C2.
Twenty of 21 pregnancies were singleton. One, C20,
was a monochorionic diamniotic twin gestation in which
only one twin had omphalocele and the other twin died
at 32 weeks of gestation (Intrauterine Fetal Death)
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without exhibiting omphalocele or other evident malfor-
mations; the cause of death was unknown.
Consanguinity was reported in case 16 (the parents
were first cousins).
Since omphalocele can be isolated at birth but
additional signs may develop during the postnatal period,
we followed up all babies for 3–84 months (Table 1). An
accurate follow-up is very important and helps the correct
diagnosis. Three newborns presented at birth with
additional signs, but these spontaneously resolved or were
considered aspecific features at the follow-up. In details,
C13 had a small interatrial defect that closed spontan-
eously during the first year of life. Given the high
prevalence of non-syndromic atrial defects (4.1:1000 live
births), we considered this as a chance association, rather
than an indication of a syndromic presentation [27]. C2
presented with slight lingual protrusion without true
macroglossia, and helix indentation. Follow-up at
48 months did not reveal any additional signs, and the
lingual protrusion spontaneously resolved. C6 had
neonatal hypoglycemia, mild neonatal hypotonia, and a
mild delay in the acquisition of motor skills (first steps
at 19 months); at 60 months, neurological development
was normal. Importantly, none of patients showed
additional clinical signs associated with BWS. Maternal
and paternal age at the conception ranged from 26 to
41 and from 28 to 48 years old, respectively. Other
known environmental risk factors [10] were also
considered and reported in the Additional file 1.
In study design/implementation STROBE guidelines
were followed.
DNA extraction
Genomic DNA was extracted from amniotic fluid (case
15) or peripheral blood lymphocytes (PBL; all other
cases and controls), using the QIAamp DNA Mini Kit
(Qiagen, Redwood City, CA, USA) according to the
manufacturer’s protocol. We also analyzed DNA from
PBL of 50 healthy controls, to investigate Variants of
Unknown Significance (VUS) in CDKN1C, and from
relatives of cases 16, 19, and 20, to investigate the inher-
itance pattern of genetic variants found in the probands.
DNA from the deceased twin of case 20 was extracted
from formalin-fixed paraffin-embedded (FFPE) material
obtained at autopsy, using a FFPE Nucleic Acid Extrac-
tion and Purification Kit (Covaris, Woburn, MA, USA),
following the manufacturer’s instructions. DNA was
quantified using a NanoDrop ND1000 spectrophotometer
(NanoDrop Technologies, Wilmington, DE, USA) and
stored at −20 °C until use.
DNA methylation analysis
We investigated the methylation level of H19/IGF2:IG-
DMR and KCNQ1OT1:TSS-DMR (four CpG sites each)
at the imprinted locus on chromosome 11p15.5, according
to previous reports [28, 29]. Sodium bisulfite conversion
of DNA samples (500 ng) was performed using the EZ
DNA Methylation-Gold Kit (Zymo Research Corporation,
Orange, CA, USA). PCRs were carried out using 40 ng of
bisulfite-converted DNA and 200 nM forward and reverse
primers, one of which was biotinylated [29]. Quantitative
DNA methylation analyses were performed using a Pyro
Mark ID instrument (Biotage AB, Uppsala, Sweden) in the
PSQ HS 96 System (Biotage), with a PyroGold SQA
reagent kit (Biotage). Hypermethylated, hypomethylated,
and normal DNA samples were included in each experi-
ment as controls. Raw data were analyzed using Q-CpG
software v1.0.9 (Biotage), which calculates the ratio of
converted to unconverted cytosines at each CpG, to deter-
mine the percentage of methylation. Results are presented
as mean values from the analyzed CpG sites ± standard
deviation (SD). Reported methylation levels represent
the mean of at least two independent experiments.
The statistical significance of differences in methylation
among samples was determined using the Student’s t-test.
We considered as “normal” H19/IGF2:IG-DMR and
KCNQ1OT1: TSS-DMR methylation ranges previously
reported by our group [28, 29].
CDKN1C and KCNQ1OT1:TSS-DMR sequencing
For CDKN1C mutation analysis, primers were designed
to amplify the two coding exons, the intron between
them, and the 5′ and 3′ UTRs. PCR conditions and
primers sequences have been previously described [30].
Sequencing of KCNQ1OT1:TSS-DMR in case 19 was
performed with primers (Forward, 5′-CACGCTGTCCA
TAAGGTGCA-3′; Reverse, 5′-TTCTCCCAGACT Control
Region 2, between the genomic positions chr11:2,699,231–
2,699,440. Fragments were amplified at an annealing
temperature of 55 °C, using 100 ng of template genomic
DNA in 1× One Taq GC reaction buffer, 0.2 μM each pri-
mer, 0.2 mM each dNTP, and 1.25 U of One Taq DNA
Polymerase (New England BioLabs, Ipswich, MA, USA).
Taq High GC Enhancer One was added to the PCR
to a final concentration of 20%. PCR products were
analyzed by 2% agarose gel electrophoresis and puri-
fied using an UltraClean PCR Clean-Up Kit (MO BIO
laboratories, Carlsbad, CA, USA), according to the
manufacturer’s instructions.
Cycle sequencing reactions of both CDKN1C and
KCNQ1OT1:TSS-DMR were carried out using the
BigDye Terminator v3.1 Cycle Sequencing Kit (Applied
Biosystems, Foster City, CA, USA) following the manu-
facturer’s protocol and analyzed on a 3130xl Genetic
Analyzer automated 16 capillary sequencer (Applied
Biosciences, Foster City, CA, USA), after purification with
a ZR DNA Sequencing Clean-up Kit (Zymo Research,
Irvine, CA, USA). Primers used for sequencing reactions
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were the same as those used for PCR. Sequences were
compared to reference genomic sequence using DNA
Dynamo software (Blue Tractor Software), and identified se-
quence variants were named according to Human Genome
Variation Society recommendations (http://www.hgvs.org/
mutnomen/). Nucleotide changes were numbered according
to Ensembl reference sequence ENST00000414822 for
CDKN1C and NCBI reference sequence NR_002728.3 for
KCNQ1OT1:TSS-DMR. Functional in silico prediction of
CDKN1C VUS was carried out using Mutation taster
(www.mutationtaster.org) and PROVEAN (Protein Variation
Effect Analyzer) databases.
Array CGH
Array CGH was performed using the Agilent Technologies
Platform (Santa Clara, CA, USA) with a SurePrint G3
Human CGH Microarray harboring 180,000 oligo-
nucleotide probes.
Labeling, purification, and hybridization of DNA
samples were carried out according to the manufac-
turer’s protocol (Agilent Oligonucleotide Array-Based
CGH for Genomic DNA Analysis, version 7.3). Slides
were scanned using a DNA Microarray Scanner (Agilent
Technologies), and TIFF images were obtained from
Agilent Scan Control software. Raw data were generated
using Agilent Feature extraction and analyzed by Agilent
Cytogenomics 3.0. Copy number variation analysis was
performed using the ADAM2 algorithm. The aberration
filter was set to detect a minimum number of three
consecutive probes/region, and the minimum absolute
average Log Ratio (MAALR) was ±0.25.
Results
Analysis of methylation of chromosome 11p15.5
In all samples, the methylation percentage at H19/
IGF2:IG-DMR was within the normal range (41–51%;
Table 2). At KCNQ1OT1:TSS-DMR, we found that 19 of
21 cases exhibited normal methylation (range: 39–50%),
whereas case 2 had slight hypomethylation (38%) and
case 19 (Fig. 2a) displayed a non-homogeneous methyla-
tion pattern at the fourth CpG site of the analyzed
region (Fig. 2b). In the latter case we hypothesized the
Table 2 Methylation and sequencing analysis of 11p15.5 locus. Methylation percentage at the two 11p15.5 Differentially Methylated
Regions, CDKN1C variants and their allelic status are reported. As already mentioned in Material and Method section, the methylation
value represents the mean of the methylation percentage at each of the four analyzed CpG sites. In addition, reported methylation
levels are the mean of at least two independent experiments
Case Nr Methylation analysis CDKN1C sequencing
H19/IGF2: IG-DMR (%) KCNQ1OT1: TSS-DMR (%) Genomic Variants Alleles
1 49.3 48.0 c.555 T>C (p.A185A) heterozygous
2 48.5 38.6a c.555 T>C (p.A185A); c.600 A > G (p.P200P) heterozygous
3 51.0 47.0 c.511_522delGCTCCGGTCGC (p.A171_A174del) homozygous
4 48.1 46.3 wildtype
5 42.0 47.0 c.555 T>C (p.A185A) heterozygous
6 47.5 47.0 c.511_522delGCTCCGGTCGC (p.A171_A174del) heterozygous
7 47.0 49.4 wildtype
8 47.0 45.3 wildtype
9 49.6 48.0 wildtype
10 49.3 47.1 wildtype
11 49.1 47.9 c.511_522delGCTCCGGTCGC (p.A171_A174del) heterozygous
12 44.3 45.3 wildtype
13 50.0 50.0 wildtype
14 44.0 45.0 c.511_522delGCTCCGGTCGC (p.A171_A174del) homozygous
15 50.0 50.0 c.-85 G>A, c.a5 + 24_a5 + 25insG heterozygous
16 48.0 48.0 c.555 T>C (p.A185A); c.624_629delGGCCCC (p.A209_P210del) homozygous
17 49.0 47.0 c.555 T>C (p.A185A) homozygous
18 45.0 49.0 c.511_522delGCTCCGGTCGC (p.A171_A174del) heterozygous
19 41.0 dysomogeneous pattern c.a5 + 24_a5 + 25insG heterozygous
20 47.0 47.0 c.555 T>C (p.A185A), c.624_629delGGCCCC (p.A209_P210del) heterozygous
21 48.0 49.0 c.511_522delGCTCCGGTCGC (p.A171_A174del) heterozygous
aslightly below the normal range
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presence of a nucleotide variant generating an arrest in
the pyrosequencing reaction of the altered strand. To
explore this possibility, we performed KCNQ1OT1:TSS-
DMR sequencing and found a heterozygous non-coding
variant G > A at nucleotide 687 (NR_002728.3) (Fig. 2c).
This nucleotide change affects the guanine of the fourth
CpG site investigated by pyrosequencing, abolishing it
and altering the global KCNQ1OT1:TSS-DMR methyla-
tion pattern. On the basis of the pyrosequencing methy-
lation pattern, we hypothesized that the modified allele
was of maternal origin. The pattern of inheritance was
indeed confirmed in parental DNA samples by Sanger
sequencing (Fig. 2a, c). The variant was also found in
the healthy maternal aunt and not in her healthy daughter
(Fig. 2a); thus the clinical significance of this alteration
remains unknown. In addition, the same nucleotide
change was identified by the 1000 Genomes project, and
is described in dbSNP (ID rs547284149) with a minor
allele frequency of 0.05%. Using a cut-off value of 1%,
we can, therefore, define this nucleotide change as a
rare variant.
CDKN1C mutation analysis
Among the 21 investigated subjects, seven did not
show any sequence alteration in CDKN1C, while 14
presented with polymorphic variants. In two of these
latter cases (cases 16 and 20), an additional variant,
c.624-629delGGCCCC (p.A209_P210del), was detected
(Fig. 1b). This variant is located in exon 1 of CDKN1C, in
the region encoding the PAPA domain of the protein
(Table 2). Patient 16 was homozygous for the deletion (the
parents were first degree cousins). Case 20 inherited the
deletion from the healthy mother and the same variant
was also present in the twin who died in utero and did not
showed omphalocele. The deletion is reported in the
dbSNP database (rs760463569) without frequency infor-
mation. We sequenced 100 CDKN1C alleles from 50 PBL
samples from healthy individuals, and the variant was not
identified (data not shown). To assess the consequence of
the p.A209_P210del on p57 protein function, we took
advantage of the in silico predictor sites MutationTaster
and Provean, and we investigated the evolutionary conser-
vation of the entire PAPA domain by a Pairwise Sequence
Alignment. Mutation Taster (www.mutationtaster.org)
analysis predicted that the variant should be classified as
“polymorphic” with a high probability (0.99); Provean
(www.provean.jvci.org) defined the effect of the deletion
as “benign” with a score of 0.489. Moreover, pairwise
alignment between the nucleotides encoding the human
PAPA domain and the corresponding sequence of mouse
CDKN1C cDNA revealed a percentage of identity lower
than 50% (alignment score: 315).
Array CGH
No evidences of copy number variants with pathogenic
significance were obtained (Additional file 2 A and B).
The 1p31.3 duplication identified by Radhakrishna et al.
[18] was not present in our cases.
Discussion
We report the analyses of the 11p15.5 locus and the
array CGH results from 21 cases with isolated
Fig. 2 CDKN1C sequence variation in C19 case. In a, the pedigree of C19 is depicted and the proband is indicated by an arrow. As shown, the
CDKN1C sequence variation (rs547284149) was inherited from the mother, was also present in the C19 maternal aunt but absent in her daughter
who did not show omphalocele. As displayed in. b, this sequence variation determined a non-homogeneous methylation pattern, with a
decrease in methylation at the fourth CpG site analyzed by pyrosequencing. The sequence variation and its maternal origin were confirmed by
sanger sequencing of KCNQ1OT1:TSS-DMR: we found a heterozygous non-coding variant G > A at nucleotide 687 (NR_002728.3) (c)
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omphalocele diagnosed during pregnancy or at birth. In
two patients additional mild signs were present, however
other specific syndromes were not suspected. Among
the 19 cases with isolated omphalocele confirmed by
follow-up, we observed a VUS (rs760463569) in
CDKN1C in two cases (cases 16 and 20) and a rare vari-
ant of KCNQ1OT1:TSS-DMR in one case (case 19).
CDKN1C sequencing analysis led to the identification of
the same deletion c.624-629delGGCCCC in two unre-
lated cases, mapping inside the highly polymorphic hex-
anucleotide tandem-repeats of exon 1, encoding the
PAPA domain of the protein. This variant is annotated
in the dbSNP database (rs760463569), however its allele
frequency, its clinical significance, and the segregation in
the dbSNP population are not reported. Moreover, the
deletion was not observed in 100 CDKN1C alleles
derived from the 50 genotyped healthy controls, there-
fore it can be classified as a rare variant with unknown
clinical significance (VUS). Further studies would be
necessary to clarify the functional impact of this variant
on the pathogenesis of the omphalocele, although we
know that the PAPA domain represents a hotspot for
CDKN1C ins/del and an extremely unstable genomic
region due to the presence of repeated stretches of hexa-
nucleotides. Moreover, the same hexanucleotide lost in
the c.624-629del has been found as an insertion in
healthy controls. Truncating mutations mapping at the
nucleotides encoding the PAPA motif have already been
described [31]. In these cases, the huge effect on gene
function is likely due to the introduction of a premature
STOP codon inside CDKN1C gene sequence.
So far, in frame ins/del of tandem repeated sequences
in the polymorphic region of PAPA domain have never
been associated with altered phenotypes. Thus, at the
moment we cannot draw a conclusion about the role of
the c.624-629del, even though the in silico predictions
and the arguments above suggest that it represent a
neutral polymorphism.
We also found a rare heterozygous maternally inherited
non-coding variant G > A at the KCNQ1OT1:TSS-DMR
locus. Interestingly, this variant alters the methylation
pattern of this DMR, resulting in its partial demethylation.
This nucleotide alteration was also present in a healthy
maternal aunt, but not in her healthy daughter, a
pattern of transmission consistent with a possible influ-
ence on the phenotype.
As mentioned above, in BWS the presence of omphalo-
cele is mainly related to KCNQ1OT1:TSS-DMR hypome-
thylation or loss-of-function mutations in the maternally
derived allele of CDKN1C. Thus, the presence of a VUS in
2 of 19 individuals (10.5%) and of a rare variant in one
case with the same rare phenotype might not be due to a
casual association, even though data supporting their
causative role are not currently available. In both cases,
the variant allele was maternally inherited, according to
the segregation pattern associated with the pathological
phenotype, but the familial segregation of the variants
could not be further investigated.
On the other hand, the presence of the G>A change in
the stillborn twin without omphalocele may indicate that
it is not clinically significant or that its penetrance is
incomplete.
Conclusions
We can surmise that alterations of methylation levels at
H19/IGF2:IG-DMR and KCNQ1OT1:TSS-DMR are not
primarily associated to omphalocele, in our cohort;
conversely, sequence variants at KCNQ1OT1:TSS-DMR
and CDKN1C could represent susceptibility factors for
the onset of isolated omphalocele. This hypothesis needs
to be validated in a wider number of patients with the
same clinical manifestation.
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